- Home
- LPAA vs CRDF Comparison
LPAA vs CRDF Comparison
Compare LPAA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPAA | CRDF |
|---|---|---|
| Founded | 2024 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 67.1M |
| IPO Year | 2024 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LPAA | CRDF |
|---|---|---|
| Price | $11.02 | $0.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.28 |
| AVG Volume (30 Days) | 6.7K | ★ 381.7K |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $10.47 | $0.76 |
| 52 Week High | $11.67 | $3.31 |
Technical Indicators
Market Signals| Indicator | LPAA | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 33.85 |
| Support Level | $10.61 | $0.77 |
| Resistance Level | $11.19 | $1.47 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 100.00 | 13.43 |
Price Performance
Historical ComparisonAbout LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.